Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

ViiV Healthcare discloses new anti-HIV compounds

Oct. 6, 2021

Shionogi licenses S-365598 to ViiV for use in ultra long-acting HIV regimens

Sep. 29, 2021

Selective functional impairment of HIV-specific CD8+ T cells heralds aborted HIV control

Sep. 28, 2021

New HIV replication inhibitors discovered at Gilead

Sep. 21, 2021

Pharmasyntez JSC identifies HIV-1 reverse transcriptase/ribonuclease H inhibitors

Sep. 16, 2021

Green light for UB-421 phase II studies in Taiwan and China for HIV

Aug. 19, 2021

Ghent University Hybrid CAR-T cell platform has dual anti-HIV effects

July 28, 2021

RNA-directed gene therapy targeting shPromA/shCCR5 tested in chronic HIV infection model

July 23, 2021

XPB shown to regulate HIV-1 transcriptional activity

July 22, 2021

IRF7 and PTDSS2 are therapeutic targets in HIV-1 infection

July 22, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...